Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) fell 2.8% during trading on Tuesday . The stock traded as low as $61.70 and last traded at $62.04. 200,522 shares changed hands during trading, an increase of 6% from the average session volume of 189,291 shares. The stock had previously closed at $63.82.
Gemini Therapeutics Stock Performance
The stock’s fifty day simple moving average is $62.50 and its two-hundred day simple moving average is $52.53. The stock has a market capitalization of $2.71 billion, a P/E ratio of -62.54 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Overbought Stocks Explained: Should You Trade Them?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
